Cellbyte, an AI-native platform built to accelerate pharmaceutical drug launches, has raised $2.75 million in seed funding. The round was led by Frontline Ventures, with participation from Y Combinator, Pace Ventures, Saras Capital, and Springboard Health Angels.
The Y Combinator-backed startup is growing at exceptional speed, reaching six figures in ARR within weeks of launch after signing major global pharmaceutical companies, including Bayer.
Fixing pharma’s most expensive and time-critical bottleneck
Bringing a new drug to market requires Market Access teams to compile extensive pricing, reimbursement, and regulatory documentation — a process slowed by fragmented datasets, legacy infrastructure, and manual workflows. As a result, it can take over 12 months for newly approved medicines to reach patients.
Pharma companies routinely spend hundreds of thousands of dollars per launch cycle accessing outdated databases or hiring third-party support.
Cellbyte aims to cut this timeline in half.
Its AI-native platform analyzes millions of data points in real time across clinical evidence, pricing databases, HTA decisions, regulatory filings, and internal documents. The result is dramatically faster, higher-quality insights that help teams prepare launch documents, model pricing scenarios, determine launch sequences, and build global go-to-market strategies.
Advertisement
A new data layer built for the AI era
Most legacy pharmaceutical databases were built long before the rise of LLMs and expose only a surface layer of information. Cellbyte instead provides a deep, interconnected, and continuously updated data foundation, enabling workflows that previously took months to be completed in minutes.
Felix Steinbrenner, Co-CEO and Co-Founder of Cellbyte, said:
“The success of a drug’s entire lifecycle is decided in its launch sequence. You need insights derived from gigabytes of accurate, up-to-date information to make the right decisions. The traction we’ve secured with some of the world’s biggest pharmaceutical companies shows the industry is ready to rethink these workflows and adopt faster, higher-quality, and more cost-effective processes.”
Daniel Moreira, Co-CEO and Co-Founder, added:
“Despite huge innovation in clinical development, pricing and market access still rely heavily on manual work and anecdotal evidence — even though information is abundant. Generative AI is changing that, and we’re proud to be driving this shift.”
Strong early traction and rapid growth
Founded in 2024 by Daniel Moreira, Felix Steinbrenner, and Samuel Moreira, Cellbyte combines deep expertise in pharmaceutical consulting, AI/ML engineering, and company building. The company has already:
- Reached six-figure ARR within weeks
- Secured contracts with Bayer and other global pharma leaders
- Expanded coverage across key international markets
- Built a product already used in high-stakes pricing and market access workflows
With the new funding, Cellbyte plans to triple its headcount, grow its engineering and data teams, and expand its presence across Europe and the US.
William McQuillan, Partner at Frontline Ventures, said:
“Cellbyte is tackling one of pharma’s biggest bottlenecks with an AI-driven strategy. Felix, Samuel, and Daniel have been global in their ambition from day one, and we’re proud to support them as they expand into the US and accelerate patient access to new treatments.”
About Cellbyte
Cellbyte is an AI-native platform that helps pharmaceutical companies accelerate drug launches worldwide. By automating pricing, market access, and regulatory workflows — and generating real-time insights from millions of data points — Cellbyte enables faster, more efficient decision-making across global markets. Backed by leading investors, the company is rapidly scaling across the US and Europe.
About Frontline Ventures
Frontline Ventures backs the most ambitious tech companies across the US and Europe. Frontline Seed supports European startups expanding into the US, while Frontline Growth invests in US scaleups expanding into Europe. Portfolio companies include MosaicML (acquired by Databricks), Navan (IPO), Pointy (acquired by Google), Vanta, and Workvivo (acquired by Zoom).
